This unique, proprietary service is exclusively available to Magnolia Medical customers as part of its Mission to ZERO® standards change management program, which combines evidence-based best practice techniques with the clinically proven Steripath® family of products.

这项独特的专有服务专为Magnolia Medical客户提供，作为其ZERO®标准变更管理计划的一部分，该计划将循证最佳实践技术与临床验证的Steripath®系列产品相结合。

SEATTLE, June 27, 2024 /PRNewswire/ -- Magnolia Medical Technologies, Inc., the inventors of the Steripath® Initial Specimen Diversion Device® (ISDD®) and the ISDD market to prevent false-positive sepsis test results, announced the launch of its highly innovative, technology-enabled service solution, Magnolia Analytics.

。

The platform, which was developed in close collaboration with several large U.S. hospital systems, enables robust quantification of clinical and economic value created by significantly reducing blood culture contamination to improve sepsis testing accuracy..

该平台是与美国几家大型医院系统密切合作开发的，可以通过显着减少血培养污染来提高败血症检测的准确性，从而对临床和经济价值进行有力的量化。。

With the launch of Magnolia Analytics, Magnolia Medical exclusively provides hospitals and healthcare systems with an end-to-end, software-driven solution to support sustained achievement of the new national standard of care for blood culture contamination performance. These new and improved standards, which are focused on patient safety and hospital financial efficiency, include the recent CDC guidelines – Blood Culture Contamination: An Overview for Infection Control and Antibiotic Stewardship Programs Working with the Clinical Laboratory..

随着Magnolia Analytics的推出，Magnolia Medical专门为医院和医疗保健系统提供端到端的软件驱动解决方案，以支持持续实现血液培养污染性能的新国家护理标准。这些新的和改进的标准侧重于患者安全和医院财务效率，包括最近的CDC指南-血培养污染：与临床实验室合作的感染控制和抗生素管理计划概述。。

This CDC document emphasizes eight clinically proven mitigation steps to prevent blood culture contamination events. The majority are based on legacy best practice techniques. However, the addition of a new step utilizing initial specimen diversion devices (ISDD) reflects the exhaustive clinical evidence demonstrating the clinical efficacy of the ISDD technology category Magnolia Medical invented.

该CDC文件强调了八个临床证明的缓解步骤，以防止血培养污染事件。大多数是基于遗留的最佳实践技术。然而，增加了一个利用初始标本转移装置（ISDD）的新步骤，反映了详尽的临床证据，证明了ISDD技术类别Magnolia Medical发明的临床疗效。

The guidelines also focus on important public health interests associated with antibiotic stewardship and antibiotic resistance risk that can be impacted by reducing blood culture contamination..

该指南还关注与抗生素管理和抗生素耐药性风险相关的重要公共卫生利益，这些风险可能会因减少血培养污染而受到影响。。

Collaborating closely with hospital customers over several years, Magnolia Medical carefully designed Magnolia Analytics to rapidly accelerate clinical performance improvement by streamlining workflows, data capture, and automated backend reporting associated with sepsis diagnostics. The platform delivers critical information to hospital department leaders as well as quality and finance administrators quantifying the value that Magnolia Medical's blood culture accuracy solutions deliver across an expansive set of clinical, quality, and economic outcome metrics..

多年来，Magnolia Medical与医院客户密切合作，精心设计了Magnolia Analytics，通过简化与败血症诊断相关的工作流程，数据采集和自动化后端报告，快速加速临床性能改进。该平台向医院部门领导以及质量和财务管理人员提供关键信息，量化Magnolia Medical的血液培养准确性解决方案在广泛的临床，质量和经济成果指标中提供的价值。。

'In response to our customer's clear unmet needs, we developed Magnolia Analytics as a custom, exclusive solution to support our hospitals in achieving and sustaining their blood culture contamination rates in line with the new benchmarks established by CDC and CLSI,' said Greg Bullington, CEO and Co-Founder of Magnolia Medical.

Magnolia Medical首席执行官兼联合创始人格雷格·布林顿（Greg Bullington）说：“为了应对客户明显未满足的需求，我们开发了Magnolia Analytics作为一种定制的独家解决方案，以支持我们的医院实现和维持其血培养污染率，使其符合CDC和CLSI制定的新基准。”。

'Truly solving the sepsis testing accuracy problem requires a combination of technology and technique. The continued adoption of Steripath and Magnolia Medical's Mission to ZERO program at nearly 500 hospitals and healthcare systems to date across the U.S. speaks to the impact of our technology solution.

“真正解决败血症检测准确性问题需要技术和技术的结合。迄今为止，美国近500家医院和医疗保健系统继续采用Steripath和Magnolia Medical的归零计划，这说明了我们的技术解决方案的影响。

The addition of Magnolia Analytics enables transparent access to performance monitoring for hospital leadership.'.

Magnolia Analytics的加入使医院领导层能够透明地进行绩效监控。”。

The Magnolia Analytics platform can also serve as an objective source of truth for hospitals that have adopted devices or process interventions whose sustained performance profiles are not supported by reliable, controlled third-party clinical evidence. By offering Magnolia Analytics to these hospital systems, Magnolia Medical provides the opportunity for an independent deep-dive assessment of the true performance of these unproven devices and interventions at the individual facility and patient level..

Magnolia Analytics平台还可以作为采用设备或过程干预措施的医院的客观真相来源，这些设备或过程干预措施的持续性能不受可靠，受控的第三方临床证据的支持。通过为这些医院系统提供Magnolia分析，Magnolia Medical为独立深入评估这些未经验证的设备和干预措施在个人设施和患者层面的真实表现提供了机会。。

With highly detailed performance data in hand, hospital customers can objectively select clinically proven solutions, including Steripath, that drive the strongest improvement in patient outcomes and greatest cost reductions – all on a sustained, measurable basis, and supported by a clinical performance guarantee..

有了高度详细的性能数据，医院客户可以客观地选择经临床验证的解决方案，包括Steripath，这些解决方案可以最大程度地改善患者预后并最大程度地降低成本，所有这些都是在持续、可测量的基础上进行的，并得到临床性能保证的支持。。

'Magnolia Analytics is an essential part of our Mission to ZERO solution, providing clinicians with confidence regarding the accuracy of blood culture results while giving our customers peace of mind that they will continually achieve validated, measurable, and sustained returns on their Steripath investment,' concluded Bullington..

布林顿总结道：“Magnolia Analytics是我们零解决方案使命的重要组成部分，为临床医生提供了对血培养结果准确性的信心，同时让我们的客户放心，他们将不断在Steripath投资中获得经过验证，可测量和持续的回报。”。。

To learn more about Magnolia Analytics, please visit magnolia-medical.com/magnolia-analytics.

要了解有关Magnolia Analytics的更多信息，请访问Magnolia-medical.com/Magnolia-Analytics。

About Steripath

关于Steripath

The Steripath® Initial Specimen Diversion Device® platform offers the only all-in-one devices that are clinically proven to meet the ENA, CDC, and CLSI evidence-based best practice guidelines to reduce blood culture contamination.1,2,3,4 To date, over 20 clinical studies, including nine peer-reviewed publications in leading clinical journals, have been completed supporting the clinical and cost effectiveness of Steripath.5.

Steripath®初始标本转移装置®平台提供了唯一经临床证明符合ENA，CDC和CLSI循证最佳实践指南以减少血培养污染的一体化装置。1,2,3,4迄今为止，已有20多项临床研究，包括领先临床期刊上的9篇同行评审出版物，已完成支持Steripath的临床和成本效益。

Steripath and Steripath Micro have been adopted by nearly 500 U.S. hospitals and healthcare systems to address the problem of blood culture contamination, which can lead to sepsis misdiagnosis resulting in unnecessary, prolonged, and harmful antibiotic treatment, extended length of hospital stay, false-positive CLABSIs, and wasted healthcare resources..

Steripath和Steripath Micro已被近500家美国医院和医疗保健系统采用，以解决血培养污染问题，这可能导致败血症误诊，导致不必要，长期和有害的抗生素治疗，延长住院时间，假阳性CLABSIs和浪费医疗资源。。

About Magnolia Medical Technologies

关于Magnolia Medical Technologies

Magnolia Medical Technologies develops, manufactures, and markets innovative blood and bodily fluid collection devices to facilitate significant improvements in the accuracy, consistency, and predictability of critical laboratory tests. Magnolia Medical invented and patented the Initial Specimen Diversion Technique® (ISDT®) and Initial Specimen Diversion Device® (ISDD®) for blood culture collection and contamination prevention.

Magnolia Medical Technologies开发，制造和销售创新的血液和体液采集设备，以促进关键实验室测试的准确性，一致性和可预测性的显着提高。。

The company has amassed an intellectual property portfolio, including more than 180 issued method, apparatus, and design patents with more than 50 additional patent applications pending. For more information, visit www.magnolia-medical.com..

该公司积累了知识产权组合，包括180多项已发布的方法、仪器和设计专利，还有50多项其他专利申请正在申请中。有关更多信息，请访问www.magnolia-medical.com。。

Blood Culture Contamination Prevention Actions: An Overview of Infection Control and Antibiotic Stewardship Programs Working with the Clinical Laboratory. 2022.

血培养污染预防行动：与临床实验室合作的感染控制和抗生素管理计划概述。2022

Principles and Procedures for Blood Cultures. 2nd Ed. CLSI Guideline M47. Clinical and Laboratory Standards Institute. 2022.

血培养的原则和程序。第二版CLSI指南M47。临床和实验室标准研究所。2022

CDC National Email Update to Clinicians. Clinicians: Use this guide to decrease blood culture contamination rates. July 2022.

CDC国家电子邮件更新给临床医生。临床医生：使用本指南可降低血培养污染率。2022年7月。

Vanhoy MA, Horigan A, Kaiser J, et al. Emergency Nurses Association (ENA). Clinical practice guideline: prevention of blood culture contamination. 2020.

Vanhoy MA，Horigan A，Kaiser J等。急诊护士协会（ENA）。临床实践指南：预防血培养污染。2020

Date on file.

存档日期。

SOURCE Magnolia Medical Technologies

来源：Magnolia Medical Technologies